StockMacro
Menu

Viridian Therapeutics

$29.96 +76% in 6 monthsMarket cap $3.4B

VRDN on XNAS, Health Care, Viridian Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue fell 64% last quarter to $25.8M while the stock rose 30% in one month.

  • BadNet loss of $453.6M over the last 12 months
  • BadShort interest is 15% of shares, 1.6 times its year-earlier level

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.

Industry
Pharmaceutical preparations (Health Care)
Employees
252
Website
viridiantherapeutics.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 25 Feb 2027 (an estimate: a year ago it reported on 26 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $25.8M, net loss $101.2M.
Quarter to 31 Dec 2021: revenue $214K, net income -$28.9MQuarter to 31 Dec 2021: revenue $214K, net income -$28.9MQuarter to 31 Mar 2022: revenue $216K, net income -$25.7MQuarter to 31 Mar 2022: revenue $216K, net income -$25.7MQuarter to 30 Jun 2022: revenue $256K, net income -$29.5MQuarter to 30 Jun 2022: revenue $256K, net income -$29.5MQuarter to 30 Sep 2022: revenue $1.2M, net income -$28.9MQuarter to 30 Sep 2022: revenue $1.2M, net income -$28.9MQuarter to 31 Dec 2022: revenue $105K, net income -$45.8MQuarter to 31 Dec 2022: revenue $105K, net income -$45.8MQuarter to 31 Mar 2023: revenue $98K, net income -$68.2MQuarter to 31 Mar 2023: revenue $98K, net income -$68.2MQuarter to 30 Jun 2023: revenue $72K, net income -$55.1MQuarter to 30 Jun 2023: revenue $72K, net income -$55.1MQuarter to 30 Sep 2023: revenue $72K, net income -$47.7MQuarter to 30 Sep 2023: revenue $72K, net income -$47.7MQuarter to 31 Dec 2023: revenue $72K, net income -$66.9MQuarter to 31 Dec 2023: revenue $72K, net income -$66.9MQuarter to 31 Mar 2024: revenue $72K, net income -$48.5MQuarter to 31 Mar 2024: revenue $72K, net income -$48.5MQuarter to 30 Jun 2024: revenue $72K, net income -$65.0MQuarter to 30 Jun 2024: revenue $72K, net income -$65.0MQuarter to 30 Sep 2024: revenue $86K, net income -$76.7MQuarter to 30 Sep 2024: revenue $86K, net income -$76.7MQuarter to 31 Dec 2024: revenue $72K, net income -$79.7MQuarter to 31 Dec 2024: revenue $72K, net income -$79.7MQuarter to 31 Mar 2025: revenue $72K, net income -$86.9MQuarter to 31 Mar 2025: revenue $72K, net income -$86.9MQuarter to 30 Jun 2025: revenue $75K, net income -$100.7MQuarter to 30 Jun 2025: revenue $75K, net income -$100.7MQuarter to 30 Sep 2025: revenue $70.6M, net income -$34.6MQuarter to 30 Sep 2025: revenue $70.6M, net income -$34.6MQuarter to 31 Dec 2025: revenue $132K, net income -$120.4MQuarter to 31 Dec 2025: revenue $132K, net income -$120.4MQuarter to 31 Mar 2026: revenue $141K, net income -$104.9MQuarter to 31 Mar 2026: revenue $141K, net income -$104.9MQuarter to 30 Jun 2026: revenue $284K, net income -$127.1MQuarter to 30 Jun 2026: revenue $284K, net income -$127.1MQuarter to 30 Sep 2026: revenue $25.8M, net income -$101.2MQuarter to 30 Sep 2026: revenue $25.8M, net income -$101.2M
31 Dec 2021RevenueNet incomeNet losstallest bar $127.1M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$25.8M-$101.2M
30 Jun 2026$284K-$127.1M
31 Mar 2026$141K-$104.9M
31 Dec 2025$132K-$120.4M
30 Sep 2025$70.6M-$34.6M
30 Jun 2025$75K-$100.7M
31 Mar 2025$72K-$86.9M
31 Dec 2024$72K-$79.7M
30 Sep 2024$86K-$76.7M
30 Jun 2024$72K-$65.0M
31 Mar 2024$72K-$48.5M
31 Dec 2023$72K-$66.9M
30 Sep 2023$72K-$47.7M
30 Jun 2023$72K-$55.1M
31 Mar 2023$98K-$68.2M
31 Dec 2022$105K-$45.8M
30 Sep 2022$1.2M-$28.9M
30 Jun 2022$256K-$29.5M
31 Mar 2022$216K-$25.7M
31 Dec 2021$214K-$28.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $26.3M $70.8M
Revenue growthRevenue of the last 12 months compared with the 12 months before. -63% +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$453.6M -$302.0M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – -464% -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – -427% -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -83.7% -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$326.3M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $955.2M $490.9M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $242.5M $20.9M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$712.7M (net cash) -$470.0M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.42 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $5.11
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. 129 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 102 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 5.9 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Viridian TherapeuticsVRDN (this company) $3.4Bloss129-63%–
Disc MedicineIRON $3.4Bloss–––
Enliven TherapeuticsELVN $3.4Bloss–––
Parabilis MedicinesPBLS $3.4B––––
Amylyx PharmaceuticalsAMLX $3.3Bloss–––
Arcutis BiotherapeuticsARQT $3.3B1116.6+60%5.9%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+9.9%

233 13F filers vs 212

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

137.1M shares held by 13F filers (30 Sep 2026) of 113.6M outstanding (2 Nov 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

15%

17.0M shares sold short (30 Oct 2026) of 113.6M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

9.1

17.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-5.3%

18.0M shares sold short in the report before, 17.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

48%

48% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 47%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

-64%

$25.8M vs $70.6M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

24

24 articles in the last 7 days; its usual week has 2 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

12×

24 articles in the last 7 days; its usual week has 2.

Unusual now sharp changes in the last 90 days, compared with its own past

  • Short interest 19.0M, 1.6× a year earlier

Price $29.96 on 20 Nov 2026, +1.7% over 12 months (12-month range $13.30 to $33.78)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders bought a net $19.6M in the last 12 months (the 12 months before: $10.0M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 4 published in the last 12 months, +33% on the 12 months before.
Revenue per quarter. Revenue $25.8M in the latest quarter, -64% on a year earlier.
Capital spending per quarter. Capital spending $370K in the latest quarter, +191% on a year earlier.
Institutional holders (13F filers). 233 13F filers reported holding it in the latest 13F quarter, +40% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
1 Sep 2026Sharp changeShort interest spike: short interest spike, 19.0M vs usual 10.4M (2026-08-14); 1.6x the same period a year earlier
18 Aug 2026Sharp changeShort interest spike: short interest spike, 19.2M vs usual 10.4M (2026-07-31); 1.6x the same period a year earlier
28 May 20268-K and other filingsA major agreement ended
17 Feb 2026Sharp changeMany funds opening a new position: many funds opening a new position, 64 vs usual 19.50 (2025-12-31); 2.2x the same period a year earlier
6 Nov 2025Sharp changeQuarterly revenue change: quarterly revenue change, 70.6M vs usual 72K (2025-09-30); 820.6x the same period a year earlier
24 Jun 20258-K and other filingsDirector or officer change
7 Apr 20258-K and other filingsDirector or officer change
10 Mar 20258-K and other filingsDirector or officer change
3 Mar 20258-K and other filingsA major agreement ended
10 Jan 20258-K and other filingsDirector or officer change
10 Jan 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
1 Oct 2024Sharp changeClustered insider buying: clustered insider buying (3 independent filers, 3 filing(s) in 30 days, value_usd total 30.6M)
20 Jun 20248-K and other filingsDirector or officer change
20 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
8 Jan 20248-K and other filingsDirector or officer change
2 Nov 20238-K and other filingsDirector or officer change
30 Oct 20238-K and other filingsDirector or officer change
17 Oct 2023Sharp changeShort interest spike: short interest spike, 9.4M vs usual 3.2M (2023-09-29); 4.4x the same period a year earlier
3 Oct 2023Sharp changeShort interest spike: short interest spike, 9.3M vs usual 2.9M (2023-09-15); 4.9x the same period a year earlier
25 Sep 20238-K and other filingsDirector or officer change
19 Sep 2023Sharp changeShort interest spike: short interest spike, 9.5M vs usual 2.8M (2023-08-31); 6.6x the same period a year earlier
12 Sep 20238-K and other filingsDirector or officer change
29 Aug 2023Sharp changeShort interest spike: short interest spike, 8.7M vs usual 2.8M (2023-08-15); 3.4x the same period a year earlier
15 Aug 2023Sharp changeShort interest spike: short interest spike, 6.2M vs usual 2.7M (2023-07-31); 2.4x the same period a year earlier
1 Aug 2023Sharp changeShort interest spike: short interest spike, 7.5M vs usual 2.7M (2023-07-14); 2.8x the same period a year earlier
18 Jul 2023Sharp changeShort interest spike: short interest spike, 6.8M vs usual 2.6M (2023-06-30); 2.9x the same period a year earlier
4 Jul 2023Sharp changeShort interest spike: short interest spike, 6.1M vs usual 2.6M (2023-06-15); 3.5x the same period a year earlier
16 Jun 20238-K and other filingsDirector or officer change
13 Jun 2023Sharp changeShort interest spike: short interest spike, 5.7M vs usual 2.6M (2023-05-31); 3.8x the same period a year earlier
30 May 2023Sharp changeShort interest spike: short interest spike, 4.4M vs usual 2.5M (2023-05-15); 3.3x the same period a year earlier
12 Apr 20238-K and other filingsDirector or officer change
6 Feb 20238-K and other filingsDirector or officer change
6 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Aug 2022Sharp changeShort interest spike: short interest spike, 2.6M vs usual 344K (2022-08-15); 38.9x the same period a year earlier
16 Aug 2022Sharp changeShort interest spike: short interest spike, 2.6M vs usual 339K (2022-07-29); 35.0x the same period a year earlier
2 Aug 2022Sharp changeShort interest spike: short interest spike, 2.6M vs usual 285K (2022-07-15); 33.3x the same period a year earlier
19 Jul 2022Sharp changeShort interest spike: short interest spike, 2.3M vs usual 195K (2022-06-30); 29.1x the same period a year earlier
28 Jun 2022Sharp changeShort interest spike: short interest spike, 1.7M vs usual 156K (2022-06-15); 20.0x the same period a year earlier
23 Jun 20228-K and other filingsDirector or officer change
23 Jun 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Jun 2022Sharp changeShort interest spike: short interest spike, 1.5M vs usual 149K (2022-05-31); 21.1x the same period a year earlier
31 May 2022Sharp changeShort interest spike: short interest spike, 1.3M vs usual 144K (2022-05-13); 11.4x the same period a year earlier
17 May 2022Sharp changeShort interest spike: short interest spike, 823K vs usual 137K (2022-04-29); 9.7x the same period a year earlier
3 May 2022Sharp changeShort interest spike: short interest spike, 533K vs usual 125K (2022-04-14); 4.8x the same period a year earlier
12 Apr 2022Sharp changeShort interest spike: short interest spike, 501K vs usual 119K (2022-03-31); 5.3x the same period a year earlier
29 Mar 2022Sharp changeShort interest spike: short interest spike, 539K vs usual 119K (2022-03-15); 4.5x the same period a year earlier
Insider net buying (open market)
Month from 1 Feb 2022: -$573K published
Month from 1 Mar 2022: -$529K published
Month from 1 Apr 2022: -$568K published
Month from 1 May 2022: -$391K published
Month from 1 Jun 2022: -$366K published
Month from 1 Aug 2022: $10.0M published
Month from 1 Nov 2022: -$179K published
Month from 1 Dec 2022: -$996K published
Month from 1 Jan 2023: -$3.4M published
Month from 1 Feb 2023: -$1.8M published
Month from 1 Mar 2023: -$711K published
Month from 1 Apr 2023: $101K published
Month from 1 Jun 2023: -$250K published
Month from 1 Jan 2024: $10.0M published
Month from 1 Sep 2024: $30.0M published
Month from 1 Oct 2024: $616K published
Month from 1 Oct 2025: $10.0M published
Month from 1 Jan 2026: -$71K published
Month from 1 May 2026: $20.0M published
Month from 1 Aug 2026: -$348K published
H-1B/E-3 applications certified
Quarter from 1 Jul 2025: 3 published
Quarter from 1 Jul 2026: 1 published
Quarter from 1 Oct 2026: 3 published
Revenue per quarter
Quarter ended 31 Dec 2021: $214K, +296% on a year earlier; public on 12 Mar 2022
Quarter ended 31 Mar 2022: $216K, -85% on a year earlier; public on 14 May 2022
Quarter ended 30 Jun 2022: $256K, -77% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $1.2M, +475% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $105K, -51% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $98K, -55% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $72K, -72% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $72K, -94% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $72K, -31% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $72K, -27% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $72K, 0% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $86K, +19% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $72K, 0% on a year earlier; public on 4 Mar 2025
Quarter ended 31 Mar 2025: $72K, 0% on a year earlier; public on 7 May 2025
Quarter ended 30 Jun 2025: $75K, +4.2% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $70.6M, +81958% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $132K, +83% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $141K, +96% on a year earlier; public on 6 May 2026
Quarter ended 30 Jun 2026: $284K, +279% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $25.8M, -64% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $84K; public on 12 Mar 2022
Quarter ended 31 Mar 2022: $179K, +1093% on a year earlier; public on 14 May 2022
Quarter ended 30 Jun 2022: $292K, +441% on a year earlier; public on 16 Aug 2022
Quarter ended 30 Sep 2022: $95K, -49% on a year earlier; public on 15 Nov 2022
Quarter ended 31 Dec 2022: $231K, +175% on a year earlier; public on 10 Mar 2023
Quarter ended 31 Mar 2023: $115K, -36% on a year earlier; public on 11 May 2023
Quarter ended 30 Jun 2023: $331K, +13% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $404K, +325% on a year earlier; public on 14 Nov 2023
Quarter ended 31 Dec 2023: $48K, -79% on a year earlier; public on 28 Feb 2024
Quarter ended 31 Mar 2024: $0, -100% on a year earlier; public on 9 May 2024
Quarter ended 30 Jun 2024: $104K, -69% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $293K, -27% on a year earlier; public on 13 Nov 2024
Quarter ended 31 Dec 2024: $114K, +138% on a year earlier; public on 4 Mar 2025
Quarter ended 31 Mar 2025: $86K; public on 7 May 2025
Quarter ended 30 Jun 2025: $42K, -60% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $127K, -57% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $240K, +111% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $23K, -73% on a year earlier; public on 6 May 2026
Quarter ended 30 Sep 2026: $370K, +191% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 51; public on 14 Feb 2022
31 Mar 2022 report: 72; public on 16 May 2022
30 Jun 2022 report: 83; public on 15 Aug 2022
30 Sep 2022 report: 100; public on 14 Nov 2022
31 Dec 2022 report: 119; public on 14 Feb 2023
31 Mar 2023 report: 131; public on 15 May 2023
30 Jun 2023 report: 125; public on 14 Aug 2023
30 Sep 2023 report: 117; public on 14 Nov 2023
31 Dec 2023 report: 123; public on 14 Feb 2024
31 Mar 2024 report: 127; public on 15 May 2024
30 Jun 2024 report: 132; public on 14 Aug 2024
30 Sep 2024 report: 160; public on 14 Nov 2024
31 Dec 2024 report: 177; public on 14 Feb 2025
31 Mar 2025 report: 173; public on 15 May 2025
30 Jun 2025 report: 168; public on 14 Aug 2025
30 Sep 2025 report: 166; public on 14 Nov 2025
31 Dec 2025 report: 225; public on 17 Feb 2026
31 Mar 2026 report: 221; public on 15 May 2026
30 Jun 2026 report: 212; public on 14 Aug 2026
30 Sep 2026 report: 233; public on 16 Nov 2026

What is unusual now

  • Made public in the last 90 days: it had 19.0M shares sold short in the 14 Aug 2026 report, 1.6× the same report last year.
  • Short interest spike: had 19.2M shares sold short in the 31 Jul 2026 report, 1.6× the same report last year Public on 12 Aug 2026.
  • Insider net buying (open market): Insiders bought a net $19.6M in the last 12 months (the 12 months before: $10.0M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 4 published in the last 12 months, +33% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 40 insider trades

No trades in the last 90 days; the latest was filed 20 Aug 2026. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
20 Aug 2026Jennifer TousignantChief Legal OfficerSellafter exercising options14,212$24.50$348KForm 4
13 May 2026Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% ownerBuy1,176,470$17.00$20.0MForm 4
2 Jan 2026Jennifer TousignantChief Legal OfficerSell2,272$31.16$71KForm 4
27 Oct 2025Fairmount Healthcare Fund II GP LLC and 2 othersDirector, 10% ownerBuy454,545$22.00$10.0MForm 4
30 Sep 2024Thomas W. BeethamChief Operating OfficerBuy5,000$23.41$117KForm 4
30 Sep 2024Stephen F. MahoneyPresident and CEOBuy21,400$23.33$499KForm 4
17 Sep 2024Fairmount Healthcare Fund II L.P. and 2 othersDirector, 10% ownerBuy1,600,000$18.75$30.0MForm 4
24 Jan 2024Fairmount Healthcare Fund II L.P. and 4 othersSee RemarksBuy476,190$21.00$10.0MForm 4

233 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 41 opened a position, 23 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)17.5M15.4%$360.5M+904K+5.4%
BlackRock, Inc.9.3M8.22%$192.1M+778K+9.1%
Paradigm Biocapital Advisors LP8.3M7.27%$170.0M+1.5M+23%
Bellevue Group AG7.1M6.26%$146.4M+377K+5.6%
Kynam Capital Management, LP6.1M5.41%$126.6M-306K-4.7%
T. Rowe Price Associates Inc5.1M4.51%-625K-11%
Fairmount Funds Management LLC5.1M4.48%$104.8MNo change
RTW Investments, LP4.9M4.32%$101.1MNew+4.9M
State Street Corp4.9M4.29%$100.4M-1.2M-20%
Vanguard Capital Management LLC4.8M4.19%$97.9M+178K+3.9%

Company events

All 78 company events

In 12 months: 2 major agreements, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
28 May 2026A major agreement ended8-K
26 May 2026Signed a major agreement8-K
11 May 2026Signed a major agreementSame filing: took on new debt8-K
22 Oct 2025Signed a major agreement8-K
20 Oct 2025Signed a major agreement8-K
30 Jul 2025Signed a major agreement8-K
24 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
7 Apr 2025Director or officer change8-K

The 5 newest of 164 articles that name the company.

Timeline

Timeline

Changes and notable records, by the date each became public

  1. 26 Aug 2026Short interest and volume change

    had 19.0M shares sold short in the 14 Aug 2026 report, 1.6× the same report last year.

    Same report last year: 11.8M; its normal report is 10.4M.

    See the evidence
    This period
    19.0M (the 14 Aug 2026 report)
    Normal report (median of 24 earlier)
    10.4M
    Typical spread (median absolute deviation)
    1.6M
    How far from its usual level
    +3.7
    Same report last year
    11.8M
    History used
    2,023 days
    2025-08-15: 11.8M2025-08-29: 11.6M2025-09-15: 11.0M2025-09-30: 10.2M2025-10-15: 10.0M2025-10-31: 9.8M2025-11-14: 9.5M2025-11-28: 9.2M2025-12-15: 9.0M2025-12-31: 8.7M2026-01-15: 8.1M2026-01-30: 7.9M2026-02-13: 7.8M2026-02-27: 7.8M2026-03-13: 8.2M2026-03-31: 10.8M2026-04-15: 10.7M2026-04-30: 11.5M2026-05-15: 14.3M2026-05-29: 14.6M2026-06-15: 15.0M2026-06-30: 17.3M2026-07-15: 18.9M2026-07-31: 19.2M2026-08-14: 19.0M
    the 14 Aug 2026 report24 earlier reportsnormal: 10.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  2. 12 Aug 2026Short interest and volume change

    had 19.2M shares sold short in the 31 Jul 2026 report, 1.6× the same report last year.

    Same report last year: 11.7M; its normal report is 10.4M.

    See the evidence
    This period
    19.2M (the 31 Jul 2026 report)
    Normal report (median of 24 earlier)
    10.4M
    Typical spread (median absolute deviation)
    1.4M
    How far from its usual level
    +4.3
    Same report last year
    11.7M
    History used
    2,009 days
    2025-07-31: 11.7M2025-08-15: 11.8M2025-08-29: 11.6M2025-09-15: 11.0M2025-09-30: 10.2M2025-10-15: 10.0M2025-10-31: 9.8M2025-11-14: 9.5M2025-11-28: 9.2M2025-12-15: 9.0M2025-12-31: 8.7M2026-01-15: 8.1M2026-01-30: 7.9M2026-02-13: 7.8M2026-02-27: 7.8M2026-03-13: 8.2M2026-03-31: 10.8M2026-04-15: 10.7M2026-04-30: 11.5M2026-05-15: 14.3M2026-05-29: 14.6M2026-06-15: 15.0M2026-06-30: 17.3M2026-07-15: 18.9M2026-07-31: 19.2M
    the 31 Jul 2026 report24 earlier reportsnormal: 10.4M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  3. 28 May 2026Filings record

    A major agreement ended

  4. 14 May 2026Insiders record

    Fairmount Healthcare Fund II L.P. (director) and 2 other(s) bought 1,176,470 shares of VRDN ($20.0M) (dated 13 May 2026)

  5. 17 Feb 2026Institutional holdings change

    saw 64 13F filers open a new position in the quarter ended 31 Dec 2025, 2.2× the same quarter last year.

    Same quarter last year: 29; its normal quarter is 19.5.

    See the evidence
    This period
    64 (the quarter ended 31 Dec 2025)
    Normal quarter (median of 8 earlier)
    19.5
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +8.6
    Same quarter last year
    29
    History used
    1,826 days
    2023-12-31: 132024-03-31: 192024-06-30: 182024-09-30: 402024-12-31: 292025-03-31: 232025-06-30: 202025-09-30: 162025-12-31: 64
    the quarter ended 31 Dec 20258 earlier quartersnormal: 19.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  6. 6 Nov 2025Financials change

    reported revenue of $70.6M for the quarter ended 30 Sep 2025, 821× the same quarter last year.

    Same quarter last year: $86K; its normal quarter is $72K.

    See the evidence
    This period
    $70.6M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $72K
    Typical spread (median absolute deviation)
    $0
    How far from its usual level
    +70.5
    Same quarter last year
    $86K
    History used
    3,470 days
    2023-09-30: $72K2023-12-31: $72K2024-03-31: $72K2024-06-30: $72K2024-09-30: $86K2024-12-31: $72K2025-03-31: $72K2025-06-30: $75K2025-09-30: $70.6M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $72K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  7. 28 Oct 2025Insiders record

    Fairmount Healthcare Fund II GP LLC (director) and 2 other(s) bought 454,545 shares of VRDN ($10.0M) (dated 27 Oct 2025)

  8. 24 Jun 2025Filings record

    Director or officer change

  9. 7 Apr 2025Filings record

    Director or officer change

  10. 10 Mar 2025Filings record

    Director or officer change

  11. 3 Mar 2025Filings record

    A major agreement ended

  12. 10 Jan 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 10 Jan 2025Filings record

    Director or officer change

  14. 1 Oct 2024Insiders change

    had 3 insiders buy $30.6M of its shares on the open market within 30 days (3 filings).

    Who bought: Mahoney Stephen F., Beetham Thomas W..

    See the evidence (3 source records)
    Independent buyers
    3
    Purchase filings (Form 4, code P)
    3
    Total bought
    $30.6M
    Window
    1 Sep 2024 to 1 Oct 2024

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

  15. 1 Oct 2024Insiders record

    Beetham Thomas W. (Chief Operating Officer) bought 5,000 shares of VRDN ($117,050) (dated 30 Sep 2024)

  16. 1 Oct 2024Insiders record

    Mahoney Stephen F. (President and CEO) bought 21,400 shares of VRDN ($499,262) (dated 30 Sep 2024)

  17. 18 Sep 2024Insiders record

    Fairmount Healthcare Fund II L.P. (director) and 2 other(s) bought 1,600,000 shares of VRDN ($30.0M) (dated 17 Sep 2024)

  18. 20 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 20 Jun 2024Filings record

    Director or officer change

  20. 25 Jan 2024Insiders record

    Fairmount Healthcare Fund II L.P. (See Remarks) and 4 other(s) bought 476,190 shares of VRDN ($10.0M) (dated 24 Jan 2024)

  21. 8 Jan 2024Filings record

    Director or officer change

  22. 2 Nov 2023Filings record

    Director or officer change

  23. 30 Oct 2023Filings record

    Director or officer change

  24. 12 Oct 2023Short interest and volume change

    had 9.4M shares sold short in the 29 Sep 2023 report, 4.4× the same report last year.

    Same report last year: 2.1M; its normal report is 3.2M.

    See the evidence
    This period
    9.4M (the 29 Sep 2023 report)
    Normal report (median of 24 earlier)
    3.2M
    Typical spread (median absolute deviation)
    869K
    How far from its usual level
    +4.9
    Same report last year
    2.1M
    History used
    973 days
    2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 2.4M2022-12-30: 2.8M2023-01-13: 2.4M2023-01-31: 2.4M2023-02-15: 2.7M2023-02-28: 2.7M2023-03-15: 2.8M2023-03-31: 3.4M2023-04-14: 3.6M2023-04-28: 3.5M2023-05-15: 4.4M2023-05-31: 5.7M2023-06-15: 6.1M2023-06-30: 6.8M2023-07-14: 7.5M2023-07-31: 6.2M2023-08-15: 8.7M2023-08-31: 9.5M2023-09-15: 9.3M2023-09-29: 9.4M
    the 29 Sep 2023 report24 earlier reportsnormal: 3.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 27 Sep 2023Short interest and volume change

    had 9.3M shares sold short in the 15 Sep 2023 report, 4.9× the same report last year.

    Same report last year: 1.9M; its normal report is 2.9M.

    See the evidence
    This period
    9.3M (the 15 Sep 2023 report)
    Normal report (median of 24 earlier)
    2.9M
    Typical spread (median absolute deviation)
    630K
    How far from its usual level
    +6.9
    Same report last year
    1.9M
    History used
    959 days
    2022-09-15: 1.9M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 2.4M2022-12-30: 2.8M2023-01-13: 2.4M2023-01-31: 2.4M2023-02-15: 2.7M2023-02-28: 2.7M2023-03-15: 2.8M2023-03-31: 3.4M2023-04-14: 3.6M2023-04-28: 3.5M2023-05-15: 4.4M2023-05-31: 5.7M2023-06-15: 6.1M2023-06-30: 6.8M2023-07-14: 7.5M2023-07-31: 6.2M2023-08-15: 8.7M2023-08-31: 9.5M2023-09-15: 9.3M
    the 15 Sep 2023 report24 earlier reportsnormal: 2.9M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  26. 25 Sep 2023Filings record

    Director or officer change

  27. 13 Sep 2023Short interest and volume change

    had 9.5M shares sold short in the 31 Aug 2023 report, 6.6× the same report last year.

    Same report last year: 1.4M; its normal report is 2.8M.

    See the evidence
    This period
    9.5M (the 31 Aug 2023 report)
    Normal report (median of 24 earlier)
    2.8M
    Typical spread (median absolute deviation)
    663K
    How far from its usual level
    +6.8
    Same report last year
    1.4M
    History used
    944 days
    2022-08-31: 1.4M2022-09-15: 1.9M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 2.4M2022-12-30: 2.8M2023-01-13: 2.4M2023-01-31: 2.4M2023-02-15: 2.7M2023-02-28: 2.7M2023-03-15: 2.8M2023-03-31: 3.4M2023-04-14: 3.6M2023-04-28: 3.5M2023-05-15: 4.4M2023-05-31: 5.7M2023-06-15: 6.1M2023-06-30: 6.8M2023-07-14: 7.5M2023-07-31: 6.2M2023-08-15: 8.7M2023-08-31: 9.5M
    the 31 Aug 2023 report24 earlier reportsnormal: 2.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 12 Sep 2023Filings record

    Director or officer change

  29. 25 Aug 2023Short interest and volume change

    had 8.7M shares sold short in the 15 Aug 2023 report, 3.4× the same report last year.

    Same report last year: 2.6M; its normal report is 2.8M.

    See the evidence
    This period
    8.7M (the 15 Aug 2023 report)
    Normal report (median of 24 earlier)
    2.8M
    Typical spread (median absolute deviation)
    594K
    How far from its usual level
    +6.7
    Same report last year
    2.6M
    History used
    928 days
    2022-08-15: 2.6M2022-08-31: 1.4M2022-09-15: 1.9M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 2.4M2022-12-30: 2.8M2023-01-13: 2.4M2023-01-31: 2.4M2023-02-15: 2.7M2023-02-28: 2.7M2023-03-15: 2.8M2023-03-31: 3.4M2023-04-14: 3.6M2023-04-28: 3.5M2023-05-15: 4.4M2023-05-31: 5.7M2023-06-15: 6.1M2023-06-30: 6.8M2023-07-14: 7.5M2023-07-31: 6.2M2023-08-15: 8.7M
    the 15 Aug 2023 report24 earlier reportsnormal: 2.8M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 10 Aug 2023Short interest and volume change

    had 6.2M shares sold short in the 31 Jul 2023 report, 2.4× the same report last year.

    Same report last year: 2.6M; its normal report is 2.7M.

    See the evidence
    This period
    6.2M (the 31 Jul 2023 report)
    Normal report (median of 24 earlier)
    2.7M
    Typical spread (median absolute deviation)
    467K
    How far from its usual level
    +5.1
    Same report last year
    2.6M
    History used
    913 days
    2022-07-29: 2.6M2022-08-15: 2.6M2022-08-31: 1.4M2022-09-15: 1.9M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 2.4M2022-12-30: 2.8M2023-01-13: 2.4M2023-01-31: 2.4M2023-02-15: 2.7M2023-02-28: 2.7M2023-03-15: 2.8M2023-03-31: 3.4M2023-04-14: 3.6M2023-04-28: 3.5M2023-05-15: 4.4M2023-05-31: 5.7M2023-06-15: 6.1M2023-06-30: 6.8M2023-07-14: 7.5M2023-07-31: 6.2M
    the 31 Jul 2023 report24 earlier reportsnormal: 2.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 26 Jul 2023Short interest and volume change

    had 7.5M shares sold short in the 14 Jul 2023 report, 2.8× the same report last year.

    Same report last year: 2.6M; its normal report is 2.7M.

    See the evidence
    This period
    7.5M (the 14 Jul 2023 report)
    Normal report (median of 24 earlier)
    2.7M
    Typical spread (median absolute deviation)
    348K
    How far from its usual level
    +9.4
    Same report last year
    2.6M
    History used
    896 days
    2022-07-15: 2.6M2022-07-29: 2.6M2022-08-15: 2.6M2022-08-31: 1.4M2022-09-15: 1.9M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 2.4M2022-12-30: 2.8M2023-01-13: 2.4M2023-01-31: 2.4M2023-02-15: 2.7M2023-02-28: 2.7M2023-03-15: 2.8M2023-03-31: 3.4M2023-04-14: 3.6M2023-04-28: 3.5M2023-05-15: 4.4M2023-05-31: 5.7M2023-06-15: 6.1M2023-06-30: 6.8M2023-07-14: 7.5M
    the 14 Jul 2023 report24 earlier reportsnormal: 2.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 13 Jul 2023Short interest and volume change

    had 6.8M shares sold short in the 30 Jun 2023 report, 2.9× the same report last year.

    Same report last year: 2.3M; its normal report is 2.6M.

    See the evidence
    This period
    6.8M (the 30 Jun 2023 report)
    Normal report (median of 24 earlier)
    2.6M
    Typical spread (median absolute deviation)
    288K
    How far from its usual level
    +9.6
    Same report last year
    2.3M
    History used
    882 days
    2022-06-30: 2.3M2022-07-15: 2.6M2022-07-29: 2.6M2022-08-15: 2.6M2022-08-31: 1.4M2022-09-15: 1.9M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 2.4M2022-12-30: 2.8M2023-01-13: 2.4M2023-01-31: 2.4M2023-02-15: 2.7M2023-02-28: 2.7M2023-03-15: 2.8M2023-03-31: 3.4M2023-04-14: 3.6M2023-04-28: 3.5M2023-05-15: 4.4M2023-05-31: 5.7M2023-06-15: 6.1M2023-06-30: 6.8M
    the 30 Jun 2023 report24 earlier reportsnormal: 2.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 28 Jun 2023Short interest and volume change

    had 6.1M shares sold short in the 15 Jun 2023 report, 3.5× the same report last year.

    Same report last year: 1.7M; its normal report is 2.6M.

    See the evidence
    This period
    6.1M (the 15 Jun 2023 report)
    Normal report (median of 24 earlier)
    2.6M
    Typical spread (median absolute deviation)
    281K
    How far from its usual level
    +8.3
    Same report last year
    1.7M
    History used
    867 days
    2022-06-15: 1.7M2022-06-30: 2.3M2022-07-15: 2.6M2022-07-29: 2.6M2022-08-15: 2.6M2022-08-31: 1.4M2022-09-15: 1.9M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 2.4M2022-12-30: 2.8M2023-01-13: 2.4M2023-01-31: 2.4M2023-02-15: 2.7M2023-02-28: 2.7M2023-03-15: 2.8M2023-03-31: 3.4M2023-04-14: 3.6M2023-04-28: 3.5M2023-05-15: 4.4M2023-05-31: 5.7M2023-06-15: 6.1M
    the 15 Jun 2023 report24 earlier reportsnormal: 2.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 16 Jun 2023Filings record

    Director or officer change

  35. 10 Jun 2023Short interest and volume change

    had 5.7M shares sold short in the 31 May 2023 report, 3.8× the same report last year.

    Same report last year: 1.5M; its normal report is 2.6M.

    See the evidence
    This period
    5.7M (the 31 May 2023 report)
    Normal report (median of 24 earlier)
    2.6M
    Typical spread (median absolute deviation)
    284K
    How far from its usual level
    +7.4
    Same report last year
    1.5M
    History used
    852 days
    2022-05-31: 1.5M2022-06-15: 1.7M2022-06-30: 2.3M2022-07-15: 2.6M2022-07-29: 2.6M2022-08-15: 2.6M2022-08-31: 1.4M2022-09-15: 1.9M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 2.4M2022-12-30: 2.8M2023-01-13: 2.4M2023-01-31: 2.4M2023-02-15: 2.7M2023-02-28: 2.7M2023-03-15: 2.8M2023-03-31: 3.4M2023-04-14: 3.6M2023-04-28: 3.5M2023-05-15: 4.4M2023-05-31: 5.7M
    the 31 May 2023 report24 earlier reportsnormal: 2.6M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 25 May 2023Short interest and volume change

    had 4.4M shares sold short in the 15 May 2023 report, 3.3× the same report last year.

    Same report last year: 1.3M; its normal report is 2.5M.

    See the evidence
    This period
    4.4M (the 15 May 2023 report)
    Normal report (median of 24 earlier)
    2.5M
    Typical spread (median absolute deviation)
    278K
    How far from its usual level
    +4.5
    Same report last year
    1.3M
    History used
    836 days
    2022-05-13: 1.3M2022-05-31: 1.5M2022-06-15: 1.7M2022-06-30: 2.3M2022-07-15: 2.6M2022-07-29: 2.6M2022-08-15: 2.6M2022-08-31: 1.4M2022-09-15: 1.9M2022-09-30: 2.1M2022-10-14: 2.2M2022-10-31: 2.3M2022-11-15: 2.8M2022-11-30: 2.9M2022-12-15: 2.4M2022-12-30: 2.8M2023-01-13: 2.4M2023-01-31: 2.4M2023-02-15: 2.7M2023-02-28: 2.7M2023-03-15: 2.8M2023-03-31: 3.4M2023-04-14: 3.6M2023-04-28: 3.5M2023-05-15: 4.4M
    the 15 May 2023 report24 earlier reportsnormal: 2.5M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 13 Apr 2023Insiders record

    Myers Scott Dunseth (Chief Executive Officer) bought 4,000 shares of VRDN ($101,480) (dated 12 Apr 2023)

  38. 12 Apr 2023Filings record

    Director or officer change

  39. 14 Mar 2023Insiders record

    Myers Scott Dunseth (Chief Executive Officer) bought 5,500 shares of VRDN ($160,325) (dated 13 Mar 2023)

  40. 6 Feb 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

Showing the newest 40 of 102 entries; narrow the window or the kind of data to see older ones.

Not listed: 195 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001590750
Ticker
VRDN
Domain
viridiantherapeutics.com
Employer name
Viridian Therapeutics, Inc. (1 unverified)
Fein
47-1187261 (1 unverified)
Hq location
MA|WALTHAM|02453 (1 unverified)
Name
MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., Viridian Securities Corporation, Viridian Therapeutics Europe Limited and 2 more
Uei
U2XJTSKPT4G3
  • DOL H-1B labor condition applications and PERM certifications25 data points7 Apr 2025 to 24 Aug 2026
  • SEC Form 13F institutional holdings216 data points31 Dec 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)222 records16 Mar 2016 to 9 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)837 data points31 Dec 2012 to 2 Nov 2026
  • SEC Form 4 insider transactions40 records, 148 data points24 Feb 2017 to 20 Aug 2026
  • FINRA short interest (twice monthly)414 data points29 Jan 2021 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)2936 data points20 Jan 2021 to 20 Nov 2026